Cargando…

Eligibility for the 4 Pharmacological Pillars in Heart Failure With Reduced Ejection Fraction at Discharge

BACKGROUND: Guidelines recommend using multiple drugs in patients with heart failure (HF) with reduced ejection fraction, but there is a paucity of real‐world data on the simultaneous initiation of the 4 pharmacological pillars at discharge after a decompensation event. METHODS AND RESULTS: A retros...

Descripción completa

Detalles Bibliográficos
Autores principales: D'Amario, Domenico, Rodolico, Daniele, Delvinioti, Agni, Laborante, Renzo, Iacomini, Chiara, Masciocchi, Carlotta, Restivo, Attilio, Ciliberti, Giuseppe, Galli, Mattia, Paglianiti, Antonio Donato, Iaconelli, Antonio, Zito, Andrea, Lenkowicz, Jacopo, Patarnello, Stefano, Cesario, Alfredo, Valentini, Vincenzo, Crea, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356099/
https://www.ncbi.nlm.nih.gov/pubmed/37382176
http://dx.doi.org/10.1161/JAHA.122.029071
_version_ 1785075198261723136
author D'Amario, Domenico
Rodolico, Daniele
Delvinioti, Agni
Laborante, Renzo
Iacomini, Chiara
Masciocchi, Carlotta
Restivo, Attilio
Ciliberti, Giuseppe
Galli, Mattia
Paglianiti, Antonio Donato
Iaconelli, Antonio
Zito, Andrea
Lenkowicz, Jacopo
Patarnello, Stefano
Cesario, Alfredo
Valentini, Vincenzo
Crea, Filippo
author_facet D'Amario, Domenico
Rodolico, Daniele
Delvinioti, Agni
Laborante, Renzo
Iacomini, Chiara
Masciocchi, Carlotta
Restivo, Attilio
Ciliberti, Giuseppe
Galli, Mattia
Paglianiti, Antonio Donato
Iaconelli, Antonio
Zito, Andrea
Lenkowicz, Jacopo
Patarnello, Stefano
Cesario, Alfredo
Valentini, Vincenzo
Crea, Filippo
author_sort D'Amario, Domenico
collection PubMed
description BACKGROUND: Guidelines recommend using multiple drugs in patients with heart failure (HF) with reduced ejection fraction, but there is a paucity of real‐world data on the simultaneous initiation of the 4 pharmacological pillars at discharge after a decompensation event. METHODS AND RESULTS: A retrospective data mart, including patients diagnosed with HF, was implemented. Consecutively admitted patients with HF with reduced ejection fraction were selected through an automated approach and categorized according to the number/type of treatments prescribed at discharge. The prevalence of contraindications and cautions for HF with reduced ejection fraction treatments was systematically assessed. Logistic regression models were fitted to assess predictors of the number of treatments (≥2 versus <2 drugs) prescribed and the risk of rehospitalization. A population of 305 patients with a first episode of HF hospitalization and a diagnosis of HF with reduced ejection fraction (ejection fraction, <40%) was selected. At discharge, 49.2% received 2 current recommended drugs, β‐blockers were prescribed in 93.4%, while a renin‐angiotensin system inhibitor or an angiotensin receptor–neprilysin inhibitor was prescribed in 68.2%. A mineralocorticoid receptor antagonist was prescribed in 32.5%, although none of the patients showed contraindications to mineralocorticoid receptor antagonist prescription. A sodium‐glucose cotransporter 2 inhibitor could be prescribed in 71.1% of patients. On the basis of current recommendations, 46.2% could receive the 4 foundational drugs at discharge. Renal dysfunction was associated with <2 foundational drugs prescribed. After adjusting for age and renal function, use of ≥2 drugs was associated with lower risk of rehospitalization during the 30 days after discharge. CONCLUSIONS: A quadruple therapy could be directly implementable at discharge, potentially providing prognostic advantages. Renal dysfunction was the main prevalent condition limiting this approach.
format Online
Article
Text
id pubmed-10356099
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-103560992023-07-20 Eligibility for the 4 Pharmacological Pillars in Heart Failure With Reduced Ejection Fraction at Discharge D'Amario, Domenico Rodolico, Daniele Delvinioti, Agni Laborante, Renzo Iacomini, Chiara Masciocchi, Carlotta Restivo, Attilio Ciliberti, Giuseppe Galli, Mattia Paglianiti, Antonio Donato Iaconelli, Antonio Zito, Andrea Lenkowicz, Jacopo Patarnello, Stefano Cesario, Alfredo Valentini, Vincenzo Crea, Filippo J Am Heart Assoc Original Research BACKGROUND: Guidelines recommend using multiple drugs in patients with heart failure (HF) with reduced ejection fraction, but there is a paucity of real‐world data on the simultaneous initiation of the 4 pharmacological pillars at discharge after a decompensation event. METHODS AND RESULTS: A retrospective data mart, including patients diagnosed with HF, was implemented. Consecutively admitted patients with HF with reduced ejection fraction were selected through an automated approach and categorized according to the number/type of treatments prescribed at discharge. The prevalence of contraindications and cautions for HF with reduced ejection fraction treatments was systematically assessed. Logistic regression models were fitted to assess predictors of the number of treatments (≥2 versus <2 drugs) prescribed and the risk of rehospitalization. A population of 305 patients with a first episode of HF hospitalization and a diagnosis of HF with reduced ejection fraction (ejection fraction, <40%) was selected. At discharge, 49.2% received 2 current recommended drugs, β‐blockers were prescribed in 93.4%, while a renin‐angiotensin system inhibitor or an angiotensin receptor–neprilysin inhibitor was prescribed in 68.2%. A mineralocorticoid receptor antagonist was prescribed in 32.5%, although none of the patients showed contraindications to mineralocorticoid receptor antagonist prescription. A sodium‐glucose cotransporter 2 inhibitor could be prescribed in 71.1% of patients. On the basis of current recommendations, 46.2% could receive the 4 foundational drugs at discharge. Renal dysfunction was associated with <2 foundational drugs prescribed. After adjusting for age and renal function, use of ≥2 drugs was associated with lower risk of rehospitalization during the 30 days after discharge. CONCLUSIONS: A quadruple therapy could be directly implementable at discharge, potentially providing prognostic advantages. Renal dysfunction was the main prevalent condition limiting this approach. John Wiley and Sons Inc. 2023-06-29 /pmc/articles/PMC10356099/ /pubmed/37382176 http://dx.doi.org/10.1161/JAHA.122.029071 Text en © 2023 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research
D'Amario, Domenico
Rodolico, Daniele
Delvinioti, Agni
Laborante, Renzo
Iacomini, Chiara
Masciocchi, Carlotta
Restivo, Attilio
Ciliberti, Giuseppe
Galli, Mattia
Paglianiti, Antonio Donato
Iaconelli, Antonio
Zito, Andrea
Lenkowicz, Jacopo
Patarnello, Stefano
Cesario, Alfredo
Valentini, Vincenzo
Crea, Filippo
Eligibility for the 4 Pharmacological Pillars in Heart Failure With Reduced Ejection Fraction at Discharge
title Eligibility for the 4 Pharmacological Pillars in Heart Failure With Reduced Ejection Fraction at Discharge
title_full Eligibility for the 4 Pharmacological Pillars in Heart Failure With Reduced Ejection Fraction at Discharge
title_fullStr Eligibility for the 4 Pharmacological Pillars in Heart Failure With Reduced Ejection Fraction at Discharge
title_full_unstemmed Eligibility for the 4 Pharmacological Pillars in Heart Failure With Reduced Ejection Fraction at Discharge
title_short Eligibility for the 4 Pharmacological Pillars in Heart Failure With Reduced Ejection Fraction at Discharge
title_sort eligibility for the 4 pharmacological pillars in heart failure with reduced ejection fraction at discharge
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356099/
https://www.ncbi.nlm.nih.gov/pubmed/37382176
http://dx.doi.org/10.1161/JAHA.122.029071
work_keys_str_mv AT damariodomenico eligibilityforthe4pharmacologicalpillarsinheartfailurewithreducedejectionfractionatdischarge
AT rodolicodaniele eligibilityforthe4pharmacologicalpillarsinheartfailurewithreducedejectionfractionatdischarge
AT delviniotiagni eligibilityforthe4pharmacologicalpillarsinheartfailurewithreducedejectionfractionatdischarge
AT laboranterenzo eligibilityforthe4pharmacologicalpillarsinheartfailurewithreducedejectionfractionatdischarge
AT iacominichiara eligibilityforthe4pharmacologicalpillarsinheartfailurewithreducedejectionfractionatdischarge
AT masciocchicarlotta eligibilityforthe4pharmacologicalpillarsinheartfailurewithreducedejectionfractionatdischarge
AT restivoattilio eligibilityforthe4pharmacologicalpillarsinheartfailurewithreducedejectionfractionatdischarge
AT cilibertigiuseppe eligibilityforthe4pharmacologicalpillarsinheartfailurewithreducedejectionfractionatdischarge
AT gallimattia eligibilityforthe4pharmacologicalpillarsinheartfailurewithreducedejectionfractionatdischarge
AT paglianitiantoniodonato eligibilityforthe4pharmacologicalpillarsinheartfailurewithreducedejectionfractionatdischarge
AT iaconelliantonio eligibilityforthe4pharmacologicalpillarsinheartfailurewithreducedejectionfractionatdischarge
AT zitoandrea eligibilityforthe4pharmacologicalpillarsinheartfailurewithreducedejectionfractionatdischarge
AT lenkowiczjacopo eligibilityforthe4pharmacologicalpillarsinheartfailurewithreducedejectionfractionatdischarge
AT patarnellostefano eligibilityforthe4pharmacologicalpillarsinheartfailurewithreducedejectionfractionatdischarge
AT cesarioalfredo eligibilityforthe4pharmacologicalpillarsinheartfailurewithreducedejectionfractionatdischarge
AT valentinivincenzo eligibilityforthe4pharmacologicalpillarsinheartfailurewithreducedejectionfractionatdischarge
AT creafilippo eligibilityforthe4pharmacologicalpillarsinheartfailurewithreducedejectionfractionatdischarge